GT Biopharma (GTBP) Non Operating Investment Income (2021 - 2024)
GT Biopharma (GTBP) posted quarterly Non Operating Investment Income of $2000.0 for Q3 2024, down 60.0% year-over-year from $5000.0 in Q4 2023, and up 100.0% quarter-over-quarter from $1000.0 in Q2 2024.
GT Biopharma (GTBP) Non Operating Investment Income (2021 - 2024) Analysis & Trends
GT Biopharma (GTBP) has reported Non Operating Investment Income for 4 consecutive years, with $2000.0 the latest figure, recorded in Q3 2024.
- In Q3 2024, Non Operating Investment Income fell 60.0% year-over-year to $2000.0; the TTM figure through Sep 2024 stood at $6000.0 (down 90.91% YoY), while the FY2023 annual figure was $48000.0, up 260.0% from the prior year.
- Non Operating Investment Income climbed to $2000.0 in Q3 2024 per GTBP's latest filing, from $1000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $29000.0 in Q1 2023 and bottomed at -$33000.0 in Q3 2021.
- Historically, Non Operating Investment Income has averaged -$769.23 across 4 years, with a median of $2000.0 in 2024.
- Annual changes were most pronounced in 2022 — Non Operating Investment Income surged 475.0% — and 2024, when it plunged 106.9%.
- GT Biopharma's Non Operating Investment Income stood at $4000.0 in 2021, then soared by 475.0% to $23000.0 in 2022, then sank by 78.26% to $5000.0 in 2023, then slumped by 60.0% to $2000.0 in 2024.
- Business Quant data shows GTBP's Non Operating Investment Income at $2000.0 in Q3 2024, $1000.0 in Q2 2024, and -$2000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 2,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Mar 31, 2024 | -2,000.00 |
| Mar 31, 2024 | -2,000.00 |
| Dec 31, 2023 | 5,000.00 |
| Dec 31, 2023 | 5,000.00 |
| Sep 30, 2023 | 5,000.00 |
| Sep 30, 2023 | 5,000.00 |
| Jun 30, 2023 | 9,000.00 |
| Jun 30, 2023 | 9,000.00 |
| Mar 31, 2023 | 29,000.00 |
| Mar 31, 2023 | 29,000.00 |
| Dec 31, 2022 | 23,000.00 |
| Dec 31, 2022 | 23,000.00 |
| Sep 30, 2022 | -23,000.00 |
| Sep 30, 2022 | -23,000.00 |
| Jun 30, 2022 | -6,000.00 |
| Jun 30, 2022 | -6,000.00 |